A recent Cleveland Clinic study challenges the efficacy of weight-loss drugs like Ozempic, finding that patients taking semaglutide and tirzepatide lost up to 50% less weight than reported in clinical trials. The study, published in Obesity Journal, analyzed nearly 8,000 obese Americans prescribed these drugs. Results showed that one in five patients stopped within three months, with up to 32% discontinuing within a year. Participants who adhered to the drugs for a year lost between 4-12% of their body weight, significantly less than the 15-21% reported in clinical trials. Reasons for discontinuation included high costs, side effects, and medication shortages. The study suggests that real-world usage patterns and maintenance dosages play a crucial role in achieving meaningful weight reductions. (Dailymail)
PHONE TOPIC: What’s the most dissatisfied you’ve ever been with a product?
